This interview reviews the implications of three recent studies — KEYNOTE-158, EMPOWER, KEYNOTE-826 — on immunotherapy in cervical cancer. In addition to the compelling connection between cervical cancer and the immune system, and therefore the interest in immunotherapy for cervical cancer, immunotherapy offers some key advantages over chemotherapy in this setting. It benefits patients with previous radiation as much as it benefits patients who are radiotherapy-naïve and it is less associated with the formation of fistulas than chemotherapy.